Scholars Central

Conference abstractPublished 1 Oct 2012

Adoptive cell therapy of cancer and autoimmune diseases employing genetically T cells with redirected antibody specificity

Authors: Zelig Eshhar

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

T cells specifically respond to their target through the TCR that recognize a complex composed of its self-MHC and peptide derived from the target antigen. To endow T cells with non-MHC restricted (nor individual-specific) restricted recognition we have designed and engineered chimeric receptor whose antigen binding unit is made of single chain Fv of a given antibody and intracellular domains of stimulating and co-stimulating molecules. Upon transduction of T-cells with such chimeric antibody- based receptor (CAR) we have demonstrated that the resulting cells (nick-named T-bodies) could function in effector T and NK cells (Teff). Using CAR specific to tumor associated antigens we created T-bodies that specifically discriminated between malignant and healthy tissues and efficiently eradicate well-established primary and disseminated tumors. We have studied different modes of adoptive cell therapy in various murine models including orthotopic grafted human prostatic, pancreatic and mammary adenocarcinoma xenografts in SCID mice as well as transgenic mice spontaneously developing mammary, or inflammation induced colorectal tumors. In all these model adoptive transfer of the tumor specific T-bodies following to mild lympho-depleting treatment yielded very pronounced antitumor responses. For complete responses and cure repeated systemic of T-bodies administration was required. In certain cases of accessible primary solid tumors direct intratumor injection of T-bodies (e.g. breast cancer) or through endoscopy (pancreatic cancer) or colonoscopy (colorectal cancer) yielded very efficient tumor eradication. Recently, we have developed a protocol to generate a universal Teff by creating time-window that allows non- matched T-bodies to cure tumor-bearing mice without causing GvH. Presently, The T-body approach found curative in pilot clinical trials.

Subjects

Biology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Cell Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Cell Science & Therapy
  • SubjectBiology
  • BylineArticles whose byline prints “Zelig Eshhar”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels